- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04801485
D-chiro Inositol in Prevention of Gestational Diabetes Mellitus in China
July 1, 2023 updated by: Women's Hospital School Of Medicine Zhejiang University
D-chiro Inositol in Prevention of Gestational Diabetes Mellitus in High Risk Pregnant Women in China
Inositol is a type of food additives, which plays an important role in insulin signal pathway and is related to insulin sensitivity.
Our randomized, double-centered, placebo-controlled study is planned to recruit 360 pregnant women who is in high risk for gestational diabetes.
They will be assumed randomly 1 g of D-chiro inositol per day or placebo from 12-16th gestational weeks until Oral Glucose Tolerance Test (OGTT) at 24-28th gestational weeks.
Perinatal outcomes about delivery time, neonatal weight will be registered.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
291
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Danqing Chen, MD
- Phone Number: 86571-87061501
- Email: Chendq@zju.edu.cn
Study Contact Backup
- Name: Xinning Chen, MD
- Email: jhviolet@163.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- Xinning Chen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- During 12-16 weeks gestation
- Meet any of the following: prepregnancy BMI > 24, family history of diabetes (type 1 or 2), GDM history, history of delivering macrosomia, gestational history of stillbirth;
- Willing to participate
Exclusion Criteria:
- Type 1 or type 2 diabetes mellitus diagnosed before pregnancy
- Multiple gestation
- Mental or cognitive impairment cannot complete the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: D-chiro inositol
500 mg twice a day
|
Active group receives inositol 1 gram per day as well as health guidance about diet and exercise.
From recruitment until OGTT.
|
Placebo Comparator: Placebo
500 mg twice a day
|
Placebo (similar appearance but not containing myo-inositol) 1 gram per day before meals.
Similar health guidance about diet and exercise.
From recruitment until OGTT.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the incidence of gestational diabetes
Time Frame: 24-28th weeks gestation
|
The number of cases and incidence of gestational diabetes according to OGTT
|
24-28th weeks gestation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the perinatal outcomes-1
Time Frame: Delivery
|
the incidence of macrosomia (macrosomia refers to a newborn weighs more than 4 kg)
|
Delivery
|
the perinatal outcomes-2
Time Frame: Delivery
|
weight gain during pregnancy (kg)
|
Delivery
|
the perinatal outcomes-3
Time Frame: Delivery
|
the Caesarean-section incidence (%)
|
Delivery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2021
Primary Completion (Actual)
November 30, 2022
Study Completion (Actual)
May 1, 2023
Study Registration Dates
First Submitted
March 4, 2021
First Submitted That Met QC Criteria
March 14, 2021
First Posted (Actual)
March 17, 2021
Study Record Updates
Last Update Posted (Actual)
July 5, 2023
Last Update Submitted That Met QC Criteria
July 1, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Pregnancy Complications
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Diabetes Mellitus
- Diabetes, Gestational
- Pregnancy in Diabetics
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Vitamin B Complex
- Inositol
Other Study ID Numbers
- IRB-20190035-R
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gestational Diabetes Mellitus in Pregnancy
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingGestational Diabetes Mellitus in PregnancyFrance
-
i-Health, Inc.CompletedGestational Diabetes Mellitus in PregnancyGermany
-
The Danish Center for Strategic Research on Type...Odense University HospitalCompletedGestational Diabetes Mellitus in PregnancyDenmark
-
Services Institute of Medical Sciences, PakistanCompletedGestational Diabetes Mellitus in PregnancyPakistan
-
Danone Asia Pacific Holdings Pte, Ltd.Nutricia ResearchTerminatedGestational Diabetes Mellitus in PregnancySingapore
-
Unity Health TorontoRecruitingGestational Diabetes Mellitus in PregnancyCanada
-
Women's Hospital School Of Medicine Zhejiang UniversityActive, not recruitingGestational Diabetes Mellitus in PregnancyChina
-
Peking Union Medical College HospitalUnknownGestational Diabetes Mellitus in PregnancyChina
-
Gulsum UysalCompletedGestational Diabetes Mellitus in PregnancyTurkey
-
Women's Hospital School Of Medicine Zhejiang UniversityQuzhou Maternal and Child Health Care Hospital; Hangzhou Jianhai Technology...Not yet recruitingGestational Diabetes Mellitus in PregnancyChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States